Pathogenic relationship between myeloproliferative neoplasms and lymphohematopoietic neoplasms / 中国实用内科杂志

The pathogenic relationship between myeloproliferative neoplasms(MPN) and lymphoid neoplasms has not been completely elucidated. With the progression of MPN treatment, the patients' survival has been prolonged owing to the use of JAK inhibitors(ruxolitinib). However, the side effects of JAK inhibitors also exist. In order to understand the natural course of this chronic disease accompanied with other hematological diseases and the characteristics and prognosis of secondary MPN, we conducted a literature review.